ISSN:
1573-7217
Keywords:
estrogen receptor
;
antiestrogen
;
tamoxifen
;
chemotherapy
;
immunotherapy
;
stage II breast cancer
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary A prospective, randomized clinical trial of adjuvant treatment of 318 stage II breast cancer patients, using chemotherapy, the antiestrogen tamoxifen, and immunotherapy is reported at 48 months follow-up. Women whose primary tumors have no estrogen receptors fall into a significantly poorer prognostic group than those whose tumors contain estrogen receptors. None of the adjuvant regimens appeared to offer any clear-cut advantage for the estrogen receptor negative patients. Those women whose primary tumor contains estrogen receptors appear to be in a prognostically favorable group, when their treatment regimen included the antiestrogen, tamoxifen. The adjuvant use of BCG immunotherapy does not appear to offer additional benefit, but the follow-up period of these treated patients is too brief to be conclusive. A longer period of observation is needed to determine whether this systemic treatment in estrogen receptor positive patients is preventing recurrence or merely delaying it.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01807895
Permalink